875858-80-3

Usage

Uses

Used in Medicinal Chemistry:
2-(4-Fluoro-Phenyl)-Thiazole-4-Carbaldehyde is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential pharmacological properties. Its unique structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Drug Design:
In the field of drug design, 2-(4-Fluoro-Phenyl)-Thiazole-4-Carbaldehyde is used as a building block for creating novel molecules with potential therapeutic applications. Its incorporation into drug candidates can lead to the discovery of new treatments for various diseases and conditions.
Used in Research and Development:
2-(4-Fluoro-Phenyl)-Thiazole-4-Carbaldehyde is utilized in research and development settings to explore its chemical properties and potential interactions with biological targets. This can contribute to a better understanding of its pharmacological profile and potential applications in medicine.
Used in Chemical Synthesis:
As a versatile chemical compound, 2-(4-Fluoro-Phenyl)-Thiazole-4-Carbaldehyde is used in the synthesis of a wide range of organic molecules, including those with potential applications in various industries such as pharmaceuticals, materials science, and agrochemicals. Its unique structure allows for the creation of new compounds with diverse properties and functionalities.

InChI:InChI=1/C10H6FNOS/c11-8-3-1-7(2-4-8)10-12-9(5-13)6-14-10/h1-6H

Upstream product

• 132089-35-1 ethyl 2-(4-fluorophenyl)thiazole-4-carboxylate 
• 22179-72-2 4-fluorothiobenzamide 
• 863668-07-9 2-(4-fluorophenyl)-1,3-thiazole-4-carboxylic acid 
• 1765-93-1 4-fluoroboronic acid 

Relevant academic research and scientific papers

Synthesis of new 2-(thiazol-4-yl)thiazolidin-4-one derivatives as potential anti-mycobacterial agents

To search for potent antimycobacterial lead compounds, a new series of 3-substituted phenyl-2-(2-(substituted phenyl)thiazol-4-yl) thiazolidin-4-one (5a-t) derivatives have been synthesized by the condensation of 2-substituted phenyl thiazole-4-carbaldehy

Synthesis, Characterization, and Antimicrobial Screening of 4″-methyl-2,2″-diaryl-4,2′:4′,5″-terthiazole Derivatives

A series of novel 4″-methyl-2,2″-diaryl-4,2′:4′,5″-terthiazole (8a-p) derivatives has been synthesized and screened for antibacterial activity against four pathogenic bacteria, Escherichia coli, Pseudomonas flurescence, Staphylococcus aureus, and Bacillus subtilis. Among them, compounds 8a and 8j exhibited excellent antibacterial activity with minimum inhibitory concentration range of 1.0 to 5.3?μg/mL and compounds 8m and 8p exhibited moderate to good antibacterial activity with minimum inhibitory concentration range of 16.9 to 29.7?μg/mL against all tested strains. All the synthesized compounds were screened for their in vitro antifungal activity against Cocinida candida. Most of the compounds reported moderate antifungal activity. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimicrobial agent.

Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives

The increase in antibiotic resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis Bacille Calmette Guerin (ATCC 35743) strains. The synthesized compounds, 5a–l were further assayed for their cytotoxic activity against the two human cancer cell lines, HeLa and human colon carcinoma 116 cell lines and showed no significant cytotoxic activity against these two cell lines at the maximum concentration evaluated. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimycobacterial agent.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).